Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study-Reference-Cited by-同舟云学术

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Published:2018-11 Issue:11 Volume:19 Page:1468-1479
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Barlesi Fabrice,Vansteenkiste Johan,Spigel David,Ishii Hidenobu,Garassino Marina,de Marinis Filippo,Özgüroğlu Mustafa,Szczesna Aleksandra,Polychronis Andreas,Uslu Ruchan,Krzakowski Maciej,Lee Jong-Seok,Calabrò Luana,Arén Frontera Osvaldo,Ellers-Lenz Barbara,Bajars Marcis,Ruisi Mary,Park Keunchil

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy;Kazandjian;Oncologist,2016

2. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1;Sul;Oncologist,2016

3. US Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer;Weinstock;Clin Cancer Res,2017

4. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

4. Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines;Cancer Immunology, Immunotherapy;2024-07-02

5. Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial;JTO Clinical and Research Reports;2024-07